<DOC>
	<DOCNO>NCT00701883</DOCNO>
	<brief_summary>A Multicenter Randomized , Double-Blind , Placebo-Controlled Study evaluate efficacy , safety tolerability MBX-8025 , novel PPAR-d agonist treat hyperlipidemia , insulin resistance obesity overweight , hyperlipidemic patient , monotherapy combination Atorvastatin Total participation patient approximately 16-17 week , may include 2 week screening period , 5 week run-in period , 8 week treatment period , 2 week follow-up . During run-in period patient take statin , statin combination Zetia undergo 'washout ' . All patient instruct follow weight-maintenance diet ( i.e. , diet prior enter study ) . They ask defer initiate weight loss diet meaningful change activity level complete study . Once randomize double blind study , patient visit clinic every two week thereafter end study . At end 8-week treatment phase , double-blind study medication discontinue . Patients attend follow visit two week final dose safety evaluation .</brief_summary>
	<brief_title>Safety Benefit MBX-8025 With Without Commonly Used Statins Moderately Overweight Patients With High Cholesterol</brief_title>
	<detailed_description>Total participation patient approximately 16-17 week , may include 2 week screening period , 5 week run-in period , 8 week treatment period , 2 week follow-up . During run-in period patient take statin , statin combination Zetia undergo 'washout ' . All patient instruct follow weight-maintenance diet ( i.e. , diet prior enter study ) . They ask defer initiate weight loss diet meaningful change activity level complete study . Once randomize double blind study , patient visit clinic every two week thereafter end study . At end 8-week treatment phase , double-blind study medication discontinue . Patients attend follow visit two week final dose safety evaluation .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Age : 1875 year Female patient must pregnant breastfeed Patients must moderately overweight All patient must abnormal cholesterol level history abnormal cholesterol level define protocol . Patients take medication low cholesterol must willing , case , discontinue medication study Stable weight ( history increase decrease 6.6 lbs [ 3 kg ] ) least 2 month prior study ; Exclusion Criteria Cancer history cancer within 5 year screen , skin cancer Patients plan elective surgery study Patients history diabetes mellitus study onset History intolerance , adverse effect atorvastatin History weight loss due stomach bypass eat disorder All patient may stroke , TIA , acute myocardial infarction , angina pectoris , coronary intervention procedure ( include limit angioplasty , stent placement , coronary revascularization ) low extremity bypass procedure , systemic intracoronary fibrinolytic therapy ) within 5 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>HDL</keyword>
	<keyword>LDL</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>